Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

Romão, Vasco C.; Vital, Edward M.; Fonseca, João Eurico; Buch, Maya H.

doi:10.1186/s13075-017-1445-3

Arthritis Research & Therapy

Table 1 Summary of proteomic studies investigating response to biologic therapy

From: Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

Biomarker	Sample size	Treatment	Main results	Reference
24 autoantibodies and cytokines^a	3 independent cohorts, n = 93	ETN	PPV 58–72% NPV 63–78%	Hueber et al. [150]
7 proteins including acute phase reactants, proteins of the complement system^b	2 independent cohorts, n = 22/16	ETN	AUC R/NR 0.86–1.0 PROS and CO7: sens 88.9%, spec 100%	Obry et al. [151]
12 cytokines and chemokines^c	n = 33	ETN	MCP1, EGF: good response CRP + EGF: good response (AUC 0.844, sens 87.5%, spec 75%)	Fabre et al. [80]
14 proteins enriched in apolipoproteins, components of the complement system and acute phase reactants^d	n = 8	IFX	NR/R ratio 1.336–5.459 AUC 0.875–1.0	Ortea et al. [152]
6 proteins signalled, 2 identified: apolipoprotein A and platelet factor 4	n = 60	IFX	AUC for all proteins 0.761–0.846 Combination: sens 97.1%, spec 97.5% Apo-A: good response, PF4: non-response	Trocmé et al. [153]
12 biomarkers assembled into one multi-biomarker disease activity (MBDA) score	n = 144	IFX vs triple tx^f	Rapid radiographic progression lower with IFX if high MBDA	Hambardzumyan et al. [154]
9 proteins differentiated response^e	n = 8	ADA	NR/R 1.42–2.18/0.42–0.73. Independence to IFX results	Ortea et al. [155]
12 cytokines and chemokines^c	n = 46	RTX	Baseline cytokines profiles not related to response	Fabre et al. [124]

Original table summarising proteomic studies available to date that aimed to investigate response to biologic therapy in rheumatoid arthritis
ADA adalimumab, AUC area under the curve, ETN etanercept, IFX infliximab, NPV negative predictive value, NR non-responder, PPV positive predictive value, R responder, sens sensitivity, spec specificity, RTX rituximab, tx therapy
^aGM-CSF, interleukin (IL)-6, fibromodulin, clusterin, ApoE, H2B/e, clusterin, HSP58, IL-1α, COMP, acetyl-calpastatin, biglycan, osteoglycin, serine protease-11, IL-1β, eotaxin, IP-10, FGF-2, MCP-1, IL-12p70, fibrinogen, FibA, IL-12p40, IL-15
^bCeruloplasmin, complement component C7 (CO7), inter-alpha-trypsin inhibitor heavy chain 1, plasminogen, vitamin K-dependent protein S (PROS), protein S100A9, zinc-alpha2-glycoprotein
^cIL-6, TNF-α, IL-1α, IL-1β, IL-2, IL-8, IFN-γ, IL-4, IL-10, monocyte chemoattractant protein (MCP)-1, epidermal growth factor (EGF), vascular endothelium growth factor
^dVitamin D-binding protein splicing variant GC-006, ceruloplasmin, apolipoprotein B-100, inter-alpha-trypsin inhibitor heavy chain H2, thrombospondin-1, complement C4-B alpha chain, inter-alpha-trypsin inhibitor heavy chain H1, gelsolin, apolipoprotein A-II, fibronectin isoform 7, complement factor H-related protein 4, apolipoprotein M, adipocyte plasma membrane-associated protein, mannan-binding lectin serine protease 2
^eTropomyosin alpha-4 chain, Transgelin-2, Cofilin-1, Hemopexin, complement C3, SH3 domain-binding glutamic acid-rich-like 3, transcription factor-like 5 protein, target of Nesh-SH3, Isoform 2 of Tropomyosin alpha-3 chain
^fTriple disease-modifying anti-rheumatic therapy: methotrexate, hydroxychloroquine, sulfasalazine

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com